Interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) is associated with considerable morbidity and mortality. In this Review, various unmet needs in the management of SSc–ILD are discussed, and solutions are proposed to help improve outcomes for these patients.

The TNF–TNF receptor signalling network has pleiotropic effects that can both promote and protect against immune-mediated diseases. Modulation of this network through the use of TNF receptor-targeting biologic drugs holds promise for treating various diseases, including TNF inhibitor-refractory diseases.

The rise in the use of digital health-care technologies such as electronic patient-reported outcome measures enables a transformation of the traditional care model. In light of the increasing demand for rheumatologists, telehealth could enable more efficient usage of scarce face-to-face appointments.

A novel combination of ceria nanoparticles and mesenchymal stem cell nanovesicles modified both inflammation and autoimmunity in a mouse model of arthritis.

Globally, rheumatic musculoskeletal diseases constitute the most common causes of disability, related morbidity and economic loss worldwide. A shortage of rheumatologists warrants education of primary care doctors in primary care rheumatology, public awareness initiatives and advocacy for rheumatic musculoskeletal health.

Using multi-omics analyses, researchers have identified two distinct immunological phenotypes of microscopic polyangiitis, which could inform prognosis and personalized treatment.

New findings support the use of targeted next-generation sequencing of NOD2 to reassess the diagnosis of juvenile idiopathic arthritis in patients with signs and symptoms suggestive of Blau syndrome.

Researchers have conducted a comprehensive single-cell analysis of synovial tissue in rheumatoid arthritis, providing insights into the heterogeneity of the disease and informing future treatment strategies.

Methotrexate reduces pain and stiffness in hand osteoarthritis with synovitis, according to the results of a new randomized controlled trial.